Gilead Sciences Inc. began its clinical testing of a late-stage, four-in-one Quad HIV tablet.
Two studies will be carried out. According to On Top Magazine, one will compare the “Quad” drug to its three-in-one HIV drug Atripla, and the other will compare to a combination of Norvir, Reyataz and Truvada, an older two-in-one drug.
Each study is expected to include about 700 patients and last for 96 weeks. Its goal is to compare the drugs’ abilities to reduce HIV levels, along with safety.
Additional studies will occur later on, comparing the various components of these drugs.
To read more on this story, visit On Top Magazine.